August 4, 2022
Now available ULTOMIRIS®
ULTOMIRIS® (ravulizumab-cwvz) injection, for intravenous or subcutaneous use, is a complement inhibitor indicated for:
• the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH)
• the treatment of adult and pediatric patients one month of age and olderwith atypical hemolytic uremic syndrome (aHUS) to inhibitcomplement-mediated thrombotic microangiopathy (TMA)
Limitations of Use:
ULTOMIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS)
• the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive